Oyster Point’s Tyrvaya Nasal Spray for Dry Eye Disease is Now Available at US Regional Wholesalers

Oyster Point’s Tyrvaya Nasal Spray for Dry Eye Disease is Now Available at US Regional Wholesalers

November 04, 2021

Tyrvaya (varenicline solution) Nasal Spray 0.03 mg is now available through US regional wholesalers for delivery to pharmacies, according to Oyster Point Pharma.

The FDA approved Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease on October 15, 2021.

Tyrvaya Nasal Spray is a highly specific cholinergic agonist that is sprayed into each nostril twice daily to trigger basal tear production.

The use of a nasal spray to treat dry eye illness is a novel technique to avoid putting medication on an already irritated ocular surface.

Furthermore, nasal administration may enable certain patients who have trouble giving topical eye drops to self-administer their dry eye condition treatment.

“We understand the impact that dry eye disease can have on patients. The urgency to provide a new treatment option for the millions of patients who live with it each day has underscored our efforts to bring Tyrvaya Nasal Spray to pharmacies quickly," John Snisarenko, Chief Commercial Officer of Oyster Point Pharma, said in a company news release.

“Oyster Point is committed to supporting the dry eye disease community by supporting access to medication for appropriate patients.”

The company has launched a patient support program called TEAMTyrvaya. For more information on the program and how to enroll, please visit https://www.tyrvaya-pro.com/www.Tyrvaya-Pro.com.